Evidence map›Paper›PMID 33987714›Full record

ArticleDiabetologia2021

Adiponectin receptor agonist AdipoRon ameliorates renal inflammation in diet-induced obese mice and endotoxin-treated human glomeruli ex vivo.

Sonja Lindfors, Zydrune Polianskyte-Prause, Rim Bouslama, Eero Lehtonen, Miia Mannerla, Harry Nisen, Jukka Tienari, Hanne Salmenkari, Richard Forsgård, Tuomas Mirtti and 3 more

Open access · hybridAbstract read
In one paragraph

Article in Diabetologia, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
7.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 64 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Perirenal Fat in Disease Progression: From Inflammatory Mediator to Therapeutic Target.International journal of urology : official journal of the Japanese Urological Association · 2025
    Review
  6. Review
  7. Obesity-related glomerulopathy: How it happens and future perspectives.Diabetic medicine : a journal of the British Diabetic Association · 2025
    Review
  8. Article
  9. Adipokines: masterminds of metabolic inflammation.Nature reviews. Immunology · 2025
    Review
  10. Podocyte-Mediated Protection from Kidney Injury.Journal of the American Society of Nephrology : JASN · 2025
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Adiposity Reduction byNutrients · 2023
    Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Neutralizing MIP3The Journal of pharmacology and experimental therapeutics · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 1 institution in 2 countries.

Sonja LindforsResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-2024-0760
Zydrune Polianskyte-PrauseResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-0145-7032
Rim BouslamaResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-2767-6759
Eero LehtonenDepartment of Pathology, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-8218-635X
Miia MannerlaResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4450-0544
Harry NisenAbdominal Center, Urology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0002-4321-3300
Jukka TienariDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0001-5735-2953
Hanne SalmenkariPharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-3418-152X
Richard ForsgårdPharmacology, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0002-1905-918X
Tuomas MirttiDepartment of Pathology, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.ORCID 0000-0003-0455-9891
Markku LehtoResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0001-8414-7285
Per-Henrik GroopResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland.ORCID 0000-0003-4055-6954
Sanna LehtonenResearch Program for Clinical and Molecular Metabolism, Faculty of Medicine, University of Helsinki, Helsinki, Finland. sanna.h.lehtonen@helsinki.fi.ORCID 0000-0003-4189-2415
University of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aims/hypothesisChronic low-grade inflammation with local upregulation of proinflammatory molecules plays a role in the progression of obesity-related renal injury. Reduced serum concentration of anti-inflammatory adiponectin may promote chronic inflammation. Here, we investigated the potential anti-inflammatory and renoprotective effects and mechanisms of action of AdipoRon, an adiponectin receptor agonist.

methodsWild-type DBA/2J mice were fed with high-fat diet (HFD) supplemented or not with AdipoRon to model obesity-induced metabolic endotoxaemia and chronic low-grade inflammation and we assessed changes in the glomerular morphology and expression of proinflammatory markers. We also treated human glomeruli ex vivo and human podocytes in vitro with AdipoRon and bacterial lipopolysaccharide (LPS), an endotoxin upregulated in obesity and diabetes, and analysed the secretion of inflammatory cytokines, activation of inflammatory signal transduction pathways, apoptosis and migration.

resultsIn HFD-fed mice, AdipoRon attenuated renal inflammation, as demonstrated by reduced expression of glomerular activated NF-κB p65 subunit (NF-κB-p65) (70%, p < 0.001), TNFα (48%, p < 0.01), IL-1β (51%, p < 0.001) and TGFβ (46%, p < 0.001), renal IL-6 and IL-4 (21% and 20%, p < 0.05), and lowered glomerular F4/80-positive macrophage infiltration (31%, p < 0.001). In addition, AdipoRon ameliorated HFD-induced glomerular hypertrophy (12%, p < 0.001), fibronectin accumulation (50%, p < 0.01) and podocyte loss (12%, p < 0.001), and reduced podocyte foot process effacement (15%, p < 0.001) and thickening of the glomerular basement membrane (18%, p < 0.001). In cultured podocytes, AdipoRon attenuated the LPS-induced activation of the central inflammatory signalling pathways NF-κB-p65, c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinase (p38-MAPK) (30%, 36% and 22%, respectively, p < 0.001), reduced the secretion of TNFα (32%, p < 0.01), and protected against podocyte apoptosis and migration. In human glomeruli ex vivo, AdipoRon reduced the LPS-induced secretion of inflammatory cytokines IL-1β, IL-18, IL-6 and IL-10. CONCLUSIONS/

interpretationAdipoRon attenuated the renal expression of proinflammatory cytokines in HFD-fed mice and LPS-stimulated human glomeruli, which apparently contributed to the amelioration of glomerular inflammation and injury. Mechanistically, based on assays on cultured podocytes, AdipoRon reduced LPS-induced activation of the NF-κB-p65, JNK and p38-MAPK pathways, thereby impelling the decrease in apoptosis, migration and secretion of TNFα. We conclude that the activation of the adiponectin receptor by AdipoRon is a potent strategy to attenuate endotoxaemia-associated renal inflammation.

Indexed as

Diet, High-FatAgedAged, 80 and overAnimalsCalcium-Binding ProteinsCytokinesDisease Models, AnimalEndotoxinsFemaleHumansImmunoblottingImmunohistochemistryKidney GlomerulusLipopolysaccharidesMaleMiceAdgre1 protein, mouseadiponectin receptor 1, mouseadiponectin receptor 2, mouseAdipoRonCalcium-Binding ProteinsCytokinesEndotoxinsLipopolysaccharidesPiperidinesReceptors, AdiponectinReceptors, G-Protein-CoupledTranscription Factor RelAAdiponectinAdipoRonDiabetesDiabetic kidney diseaseInflammationInflammatory cytokinesLPSObesityObesity-related kidney diseasePodocyte

Identifiers

PMID33987714
PMCPMC8245393
OpenAlexW3162068390

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.